Περίληψη:
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL. © 2015 by The American Society of Hematology 10.1182/blood-2014-09-600874.
Συγγραφείς:
Baliakas, P.
Agathangelidis, A.
Hadzidimitriou, A.
Sutton, L.-A.
Minga, E.
Tsanousa, A.
Scarfò, L.
Davis, Z.
Yan, X.-J.
Shanafelt, T.
Plevova, K.
Sandberg, Y.
Vojdeman, F.J.
Boudjogra, M.
Tzenou, T.
Chatzouli, M.
Chu, C.C.
Veronese, S.
Gardiner, A.
Mansouri, L.
Smedby, K.E.
Pedersen, L.B.
Moreno, D.
Van Lom, K.
Giudicelli, V.
Francova, H.S.
Nguyen-Khac, F.
Panagiotidis, P.
Juliusson, G.
Angelis, L.
Anagnostopoulos, A.
Lefranc, M.-P.
Facco, M.
Trentin, L.
Catherwood, M.
Montillo, M.
Geisler, C.H.
Langerak, A.W.
Pospisilova, S.
Chiorazzi, N.
Oscier, D.
Jelinek, D.F.
Darzentas, N.
Belessi, C.
Davi, F.
Ghia, P.
Rosenquist, R.
Stamatopoulos, K.
Λέξεις-κλειδιά:
adult; adult; amino acid composition; amino acid composition; Article; cancer patient; cancer patient; cancer prognosis; cancer prognosis; chronic lymphatic leukemia; chronic lymphatic leukemia; female; female; gene mutation; gene mutation; human; human; IGHV3 21 gene; IGHV3 21 gene; in situ hybridization; in situ hybridization; major clinical study; major clinical study; male; male; priority journal; priority journal; prospective study; prospective study; tumor gene; tumor gene; aged; B lymphocyte; drug effects; gene expression regulation; gene rearrangement; genetic heterogeneity; genetics; immunology; Leukemia, Lymphocytic, Chronic, B-Cell; middle aged; mortality; pathology; prognosis; somatic hypermutation; survival analysis; time to treatment; treatment outcome, antineoplastic agent; immunoglobulin heavy chain, Aged; Antineoplastic Agents; B-Lymphocytes; Female; Gene Expression Regulation, Leukemic; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genetic Heterogeneity; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Somatic Hypermutation, Immunoglobulin; Survival Analysis; Time-to-Treatment; Treatment Outcome
